ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för MK-2206. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

27 träffar

Bibliografisk träff 2024-08-23

The novel secretome ST266 activates Akt and protects against oxidative stress-mediated injury in human RPE and Müller cells.

Tang AC, Besley NA, Trimpey-Warfhatig R, Yang P, Wessel H, Brown L, Kirshner Z, Jaffe GJ.

Exp Eye Res · journal article · DOI 10.1016/j.exer.2024.110060

Bibliografisk träff 2024-05-28

Spatiotemporal release of non-nucleotide STING agonist and AKT inhibitor from implantable 3D-printed scaffold for amplified cancer immunotherapy.

Wang H, Liu Z, Fang Y, Luo X, Zheng C, Xu Y, Zhou X, Yuan Q, Lv S, Ma L, Lao YH, Tao Y, Li M.

Biomaterials · journal article · DOI 10.1016/j.biomaterials.2024.122645

Bibliografisk träff 2023-12-01

AKT inhibition sensitizes acute leukemia cells to S63845-induced apoptosis.

Li Y, Du L, Ye K, Sun X, Hu L, Gao S, Dai H.

Hematology · journal article · DOI 10.1080/16078454.2023.2214465

Bibliografisk träff 2023-11-10

A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).

Ho AL, Foster NR, Deraje Vasudeva S, Katabi N, Antonescu CR, Frenette GP, Pfister DG, Erlichman C, Schwartz GK.

Cancer · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/cncr.35103

Bibliografisk träff 2023-07-13

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells.

Gao HL, Cui Q, Wang JQ, Ashby CR, Chen Y, Shen ZX, Chen ZS.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2023.1235285

Bibliografisk träff 2023-03-01

CircLASP1 silence strengthens the therapeutic effects of MK-2206 on nasopharyngeal cancer through upregulating miR-625.

Xu LN, Liu SL, Yang Y, Shu L, Sun Y.

Cancer Sci · research-article; journal article · DOI 10.1111/cas.15725

Bibliografisk träff 2022-11-28

Remote Ischemic Conditioning Enhances Collateral Circulation Through Leptomeningeal Anastomosis and Diminishes Early Ischemic Lesions and Infarct Volume in Middle Cerebral Artery Occlusion.

Saito M, Hoshino T, Ishizuka K, Iwasaki S, Toi S, Shibata N, Kitagawa K.

Transl Stroke Res · journal article · DOI 10.1007/s12975-022-01108-2

Bibliografisk träff 2022-11-05

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro.

Chen M, Yu Y, Mi T, Guo Q, Xiang B, Tian X, Jin L, Long C, Shen L, Liu X, Pan J, Zhang Y, Xu T, Zhang D, Wei G.

Cells · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/cells11213505

Bibliografisk träff 2022-11-04

Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line.

Guvenir Celik E, Eroglu O.

Mol Biol Rep · journal article · DOI 10.1007/s11033-022-08034-4

Bibliografisk träff 2022-08-03

Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells.

Gong B, Zhang J, Hua Z, Liu Z, Thiele CJ, Li Z.

Front Oncol · published erratum; correction · DOI 10.3389/fonc.2022.984514

Bibliografisk träff 2022-04-13

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.

Ma Y, Sender S, Sekora A, Kong W, Bauer P, Ameziane N, Al-Ali R, Krake S, Radefeldt M, Weiss FU, Lerch MM, Parveen A, Zechner D, Junghanss C, Murua Escobar H.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms23084295

Bibliografisk träff 2022-04-01

Evaluating the Effects of Separate and Concomitant Use of MK-2206 and Salinomycin on Prostate Cancer Cell Line.

Savaee M, Bakhshi A, Yaghoubi F, Pourrajab F, Goodarzvand Chegini K.

Rep Biochem Mol Biol · research-article; journal article · DOI 10.52547/rbmb.11.1.157

Bibliografisk träff 2022-03-31

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.

Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA.

Gynecol Oncol Rep · journal article; case reports; case-report · DOI 10.1016/j.gore.2022.100974

Bibliografisk träff 2021-10-19

The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calreticulin Gene Mutation.

Wang C, Hu X, Wan Y, Wang S, Qi K, Li Y, Qiao J, Zeng L, Li Z, Fu C, Xu K.

Chemotherapy · journal article · DOI 10.1159/000518921

Bibliografisk träff 2021-07-12

Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells.

Gong B, Zhang J, Hua Z, Liu Z, Thiele CJ, Li Z.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2021.686898

Bibliografisk träff 2021-05-27

Co-Administration of Anticancer Candidate MK-2206 Enhances the Efficacy of BCG Vaccine Against <i>Mycobacterium tuberculosis</i> in Mice and Guinea Pigs.

Bouzeyen R, Chugh S, Gosain TP, Barbouche MR, Haoues M, Rao KVS, Essafi M, Singh R, Singh R.

Front Immunol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3389/fimmu.2021.645962

Bibliografisk träff 2021-03-26

Central and peripheral emetic loci contribute to vomiting evoked by the Akt inhibitor MK-2206 in the least shrew model of emesis.

Zhong W, Chebolu S, Darmani NA.

Eur J Pharmacol · research-article; journal article · DOI 10.1016/j.ejphar.2021.174065

Bibliografisk träff 2021-03-09

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.

Richter A, Fischer E, Holz C, Schulze J, Lange S, Sekora A, Knuebel G, Henze L, Roolf C, Murua Escobar H, Junghanss C.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms22052771

Bibliografisk träff 2020-08-01

A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer.

Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL, Spreafico A, LoConte N, Anders NM, Miles T, Rudek MA, Doyle LA, Nelkin B, Maitra A, Azad NS, ETCTN-9231 Study Team.

Clin Transl Sci · research-article; clinical trial, phase i; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1111/cts.12802

Bibliografisk träff 2020-02-14

Combination of Rapamycin and MK-2206 Induced Cell Death <i>via</i> Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines.

Dong Y, Gong W, Hua Z, Chen B, Zhao G, Liu Z, Thiele CJ, Li Z.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2020.00031

Bibliografisk träff 2020-01-14

Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine.

Wang Z, Luo G, Qiu Z.

Oncol Lett · research-article; journal article · DOI 10.3892/ol.2020.11300

Bibliografisk träff 2019-12-13

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.

Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN.

Int J Cancer · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/ijc.32783

Bibliografisk träff 2019-11-06

The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells.

Li YL, Weng HC, Hsu JL, Lin SW, Guh JH, Hsu LC.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2019.01311

Bibliografisk träff 2019-08-28

A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.

Mehnert JM, Kaveney AD, Malhotra J, Spencer K, Portal D, Goodin S, Tan AR, Aisner J, Moss RA, Lin H, Bertino JR, Gibbon D, Doyle LA, White EP, Stein MN.

Cancer Chemother Pharmacol · clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1007/s00280-019-03919-x

Bibliografisk träff 2019-04-03

Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.

Djuzenova CS, Fiedler V, Memmel S, Katzer A, Sisario D, Brosch PK, Göhrung A, Frister S, Zimmermann H, Flentje M, Sukhorukov VL.

BMC Cancer · research-article; journal article · DOI 10.1186/s12885-019-5517-4

Bibliografisk träff 2018-11-01

MK-2206 window of opportunity study in breast cancer.

Akcakanat A, Meric-Bernstam F.

Ann Transl Med · comment; editorial · DOI 10.21037/atm.2018.10.32

Bibliografisk träff 2018-07-22

Augmentation of Ouabain-Induced Increase in Heart Muscle Contractility by Akt Inhibitor MK-2206.

Buzaglo N, Golomb M, Rosen H, Beeri R, Ami HC, Langane F, Pierre S, Lichtstein D.

J Cardiovasc Pharmacol Ther · research support, non-u.s. gov't; journal article · DOI 10.1177/1074248418788301